Table 1.
Author | Design | N | Subjects | Country | Cancer | Exposure | Results |
---|---|---|---|---|---|---|---|
Ferreros [21*] | Cohort | 7,186 | HIV(+) and HIV(−) IDU |
Spain | Any NADM (fatal) |
1987–96, 1997–2004 |
HIV(+): RR=1.3 (95% CI=0.7–2.4) HIV(−): RR=1.9 (95% CI=0.8–4.5) |
Patel [22**] | Cohort | 54,780 | HIV(+) | USA | Multiple subtypes |
1992–95, 1996–99, 2000–03 |
Increasing: anal (p<0.001), Hodgkin's (p=0.03), melanoma (p<0.05), colorectal (0.03), prostate (p=0.01). No significant trend for other cancers (p>0.05). Only anal cancer increased over time relative to general population (p<0.001). |
Engels [23**] | Registry match |
57,350 | HIV(+) | USA | Multiple subtypes |
1991–95, 1996–2002 |
Liver: RR=infinite (one-sided p=0.03) Hodgkin's: RR=2.7 (95% CI=1.0–7.1) Other cancers not significant (p>0.05) |
Hessol [24*] | Registry match |
14,210 | AIDS | USA | Multiple subtypes |
1990–95, 1996–2000 |
Anal: HR=2.7 (95% CI=1.0–7.3) All other cancers not significant (p>0.05) |
Long [25*] | Cohort | 2,566 | HIV(+) | USA | Multiple subtypes |
1996–97, 1998–99, 2000–01, 2002–03, 2004–05 |
No significant trend (p>0.05) |
Piketty [26**] | Cohort | 86,322 | HIV(+) | France | Anal | 1992–3/96, 4/1996–98, 1999–2000, 2001–02, 2003–04 |
Higher rates before vs. after 3/1996 (p>0.05). No trends between 4/1996–2004 (p>0.05) |
Chaturvedi [27**] | Registry match |
397,927 | AIDS | USA | Lung | 1980–89, 1990–95, 1996–2002 |
No significant trend (p>0.05) |
Kirk [28**] | Cohort | 2,086 | HIV(+) and HIV(−) IDU |
USA | Lung (fatal) | 1988-6/96, 7/96-not stated |
No significant trend (p>0.05) |
Rimland [29*] | Cohort | 2,999 | HIV(+) | USA | Prostate | 1982–2002, 2003-not stated |
Increasing trend (p<0.001) |
Crum-Cianflone [30] | Cohort | 4,507 | HIV(+) | USA | Skin | 1987–96, 1997–2006 |
No significant trend (p>0.05) |
HR, hazard ratio; IDU, injection drug users; NADM, non-AIDS-defining malignancy; RR, risk ratio